Our immune system is capable of a remarkable feat: the ability to remember infections for years, even decades, after they have first been encountered and defeated.
Researchers have demonstrated an approach to HIV vaccine design that uses an altered form of HIV's outer coating or envelope protein. The design could bind better to immature B cell receptors creating an enhanced immune response.
Drugmaker Pfizer Inc. for a second time is extending its tender offer for pain drug developer Icagen, as the number of shares tendered again fell short of what Pfizer needed.
Researchers have discovered that dendritic cells in the liver have a protective role against the toxicity of acetaminophen, the widely used over-the-counter pain reliever and fever reducer for adults and children.
French drugmaker Sanofi SA will begin selling a generic version of Pfizer's Lipitor, at nearly $11 billion a year starting in the spring of 2012.
Selecta Biosciences, Inc. announced that Science Applications International Corporation (SAIC) awarded them a subcontract to develop a targeted synthetic vaccine particle product for malaria.
A meta-analysis reaffirms the safety profile of aspirin for short-term treatment of mild to moderate pain, and aches and fever due to colds when used as directed.
Metabolon, Inc.’s study, “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” establishes the strong association of biochemical levels with the genetics of an individual and illustrates the power of combining metabolomics with genomics analyses.
The Cedex Bio Bioprocess Analyzer from Roche is a continuous random-access analyser, enabling for a safe and reliable determination of chemical and biochemical parameters in aqueous solutions.
Tecan has launched the HP D300 Digital Dispenser, a standalone instrument for the pharmaceutical sector, which uses HP Direct Digital Dispensing technology to rapidly deliver picoliter to microliter volumes of drug compounds.
HemoShear, LLC announced that it has been awarded up to $4.3 million in a Phase 1 Small Business Innovation Research grant award from the National Heart, Lung and Blood Institute of the National Institutes of Health.
A new saliva test can measure the amount of potential carcinogens stuck to a person's DNA, interfering with the action of genes involved in health and disease, and could lead to a commercial test to help determine risks for cancer and other diseases.
MorphoSys AG announced that the first patient in a Phase 1/2a clinical trial of its cancer antibody MOR202 has been dosed. MOR202 is directed against a therapeutic target which is highly expressed in blood cancers.
ReNeuron Group reports that the Data Safety Monitoring Board for the Phase 1 clinical trial of its ReN001 stem cell therapy for stroke patients has recommended that the trial advances to the evaluation of a higher dose of ReN001.
Researchers have reported results from a trial that showed that an intravenously-delivered viral therapy can consistently infect and spread within tumors without harming normal tissues in humans.